Ravulizumab (Ultomiris)

Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses Ravulizumab (Ultomiris) for IV infusion, 10 mg/mL and 100 mg/mL concentrate for solution for IV infusion. Indication: For the treatment of adult patients with anti–AChR antibody–positive gMG